Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • T002: Treatment related morbid...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

Bibliographic Details
Main Authors: Peter Borchmann, Alden Moccia, Richard Greil, Mark Herzberg, Alexander Fosså, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Valdete Schaub, Mathias Hänel, Urban Novak, Julia Meissner, Johannes Hellmuth, Stephan Mathas, Josée. M. Zijlstra, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratush Giri, Stefanie Kreissl, Michael Fuchs, Gundolf Schneider, Andreas Rosenwald, Wolfram Klapper, Hans Theodor Eich, Christian Baues, Michael Hallek, Carsten Kobe, Volker Diehl, Andreas Engert
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000890576.23258.1c
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000890576.23258.1c

Similar Items

  • P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
    by: Paul J. Bröckelmann, et al.
    Published: (2022-10-01)
  • S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL
    by: P. Bröckelmann, et al.
    Published: (2022-06-01)
  • T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
    by: Dennis A. Eichenauer, et al.
    Published: (2022-10-01)
  • Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma
    by: Andreas Engert, et al.
    Published: (2017-12-01)
  • The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
    by: Peter Borchmann, et al.
    Published: (2018-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs